OR WAIT null SECS
Analytical technology company AB SCIEX is to collaborate with the University of Geneva's Mass Spectrometry Centre to create new workflows and analytical strategies intended to improve drug discovery and development.
Analytical technology company AB SCIEX is to collaborate with the University of Geneva’s Mass Spectrometry Centre to create new workflows and analytical strategies intended to improve drug discovery and development. This collaboration is focused on developing specific applications for use with a mass spectrometry system from the company that it claims combines both qualitative and quantitative analysis at high resolution and high sensitivity with accurate mass.
“This new innovation, which is supported by strategies for metabolite identification developed in collaboration with the University of Geneva, will provide the pharmaceutical industry with a unique workflow solution to improve drug discovery and development”, said Laura Lauman, the company’s president, in a statement.
The mass spectrometry centre will apply the technology for metabolite identification. Having the capabilities to simultaneously identify metabolites with high resolution accurate mass and quantify them with high sensitivity would allow the scientists in Geneva to develop advanced workflows and software applications that are expected to help accelerate the adoption of the new platform within the pharmaceutical industry.
“The ability to integrate qualitative and quantitative analysis within a single platform enables new and better ways to think about conducting experiments. By developing novel workflows to take advantage of the new platform, we will be able to better understand biological systems and improve the drug discovery process”, said Gerard Hopfgartner, professor and scientist at the university, in a statement.
For more information on the company visit www.absciex.com